Page last updated: 2024-11-11

verlukast

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

verlukast: LTD4 receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6509849
CHEMBL ID280481
SCHEMBL ID37246
MeSH IDM0164601

Synonyms (40)

Synonym
HY-76511
verlukast
D02384
120443-16-5
verlukast (usan/inn)
mk-0679
mk 0679
mk-679
CHEMBL280481 ,
l-668,019
bdbm50013920
3-[(r)-{3-[(e)-2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-(2-dimethylcarbamoyl-ethylsulfanyl)-methylsulfanyl]-propionic acid
3-[(r)-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-[3-(dimethylamino)-3-oxopropyl]sulfanylmethyl]sulfanylpropanoic acid
l 668,019
verlukast [usan:inn]
5q9o54p0h7 ,
propanoic acid, 3-(((3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)-, (r-(e))-
l 668019
r-(-)-mk 571
unii-5q9o54p0h7
3-(((alphar)-m-((e)-2-(7-chloro-2-quinolyl)vinyl)-alpha-((2-(dimethylcarbamoyl)ethyl)thio)benzyl)thio)propionic acid
mk 679
verlukastum [inn-latin]
verlukastum
CS-0367
verlukast [usan]
verlukast [inn]
3-(((.alpha.r)-m-((e)-2-(7-chloro-2-quinolyl)vinyl)-.alpha.-((2-(dimethylcarbamoyl)ethyl)thio)benzyl)thio)propionic acid
gtpl6193
mk679
3-[(r)-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-(3-dimethylamino-3-oxopropyl)sulfanylmethyl]sulfanylpropanoic acid
3-[[(r)-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-propanoic acid
SCHEMBL37246
mk-679; l 668019;mk-0679;mk0679;l668019;l-668019
propanoic acid, 3-[[(r)-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-
(r,e)-3-(((3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid
Q27089139
MS-29567
propanoicacid,3-[[(r)-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-
AKOS040744410

Research Excerpts

Overview

Verlukast (MK-0679) is a potent leukotriene D4 antagonist. It was under development for the treatment of bronchial asthma.

ExcerptReferenceRelevance
"Verlukast (MK-0679) is a potent leukotriene D4 antagonist that was under development for the treatment of bronchial asthma. "( Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile.
Gupta, N; Nicoll-Griffith, DA; Trimble, LA; Twa, SP; Williams, H; Yergey, JA, 1995
)
3.18

Toxicity

ExcerptReferenceRelevance
"4-Hydroxynonenal (4HNE) is the most prevalent toxic lipid peroxidation product formed during oxidative stress."( Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal.
de Vries, EE; Hooiveld, GJ; Jansen, PL; Krikken, I; Müller, M; Renes, J, 2000
)
0.31
" These toxic effects were modestly increased by inhibition of Mrp1 activity with 3-([3-(2-[7-chloro-2-quinolinyl]ethenyl)phenyl-(3-dimethylamino-3-oxopropyl)-thio-methyl]thio)propanoic acid (MK571)."( Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1).
Caniglia, S; Fernetti, C; Gennuso, F; L'Episcopo, F; Marchetti, B; Morale, MC; Ostrow, JD; Pascolo, L; Testa, N; Tiribelli, C; Tirolo, C, 2004
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
"The influence of dose and food on the pharmacokinetic profile of orally administered verlukast, a leukotriene D4 receptor antagonist, was investigated in 12 healthy male volunteers."( Oral pharmacokinetics and food interaction of the leukotriene D4 receptor antagonist verlukast.
Bjornsson, TD; Hsieh, JY; Lin, CC; Margolskee, DJ; Rogers, JD; Schwartz, JI; Williams, VC, 1993
)
0.73
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" A heterocyclic compound, BPCPU [1-(1-(4-bromophenyl)-3-carbamoyl-1H-pyrazol-4-yl) urea], which was metabolically stable in vitro in rat liver microsomes and freshly isolated rat hepatocytes, demonstrated a saturable nonlinear pharmacokinetic profile in the rat."( Saturation of multidrug-resistant protein 2 (mrp2/abcc2)-mediated hepatobiliary secretion: nonlinear pharmacokinetics of a heterocyclic compound in rats after intravenous bolus administration.
Heyde, BR; Hu, Y; Lai, Y; Li, N; Mandrell, KM; Sampson, KE; Zutshi, A, 2009
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" Also, the bioavailability of MK-679 was determined in six healthy males receiving simultaneously an oral dose of 250 mg of MK-679 and intravenous infusion of 1 mg 14C-MK-679."( The bioavailability and nonlinear pharmacokinetics of MK-679 in humans.
Amin, RD; Cheng, H; Ebel, DL; Lasseter, KC; Lin, C; Rogers, JD; Schwartz, JI; Seibold, JR; Tocco, DJ, 1994
)
0.29
" The failure of a receptor blocker of leukotrienes to moderate disease expression suggests either a less important role for these chemicals in AOM or an insufficient bioavailability of the specific MK 571 inhibitor."( Expression of acute otitis media after receptor blockade of platelet activating factor, thromboxane, and leukotrienes in the chinchilla.
Alper, CM; Burckart, GJ; Diven, WF; Doyle, WJ; Evans, RW; Jaffe, R, 1998
)
0.3
" It also provides additional explanation why raloxifene has low bioavailability but a long half-life."( Disposition mechanisms of raloxifene in the human intestinal Caco-2 model.
Hu, M; Jeong, EJ; Lin, H, 2004
)
0.32
" This points to flavonoid-mediated stimulation of the bioavailability of PhIP and, thus, a possible adverse effect of these supposed beneficial food ingredients."( An in vitro and in silico study on the flavonoid-mediated modulation of the transport of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) through Caco-2 monolayers.
Alink, GM; Freidig, AP; Groten, JP; Rietjens, IM; Schutte, ME; van de Sandt, JJ, 2006
)
0.33
" Low ocular bioavailability of drugs has been attributed primarily to low permeability across corneal epithelium, thus leading to sub-therapeutic concentrations of drug in the eye and treatment failure."( Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux.
Karla, PK; Mitra, AK; Pal, D; Quinn, T, 2007
)
0.34
" In conclusion, this study presents direct evidence that LVR is effluxed by both P-gp and MRP2 which may contribute to its poor oral bioavailability and limited penetration into the CNS."( Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor.
Agarwal, S; Mitra, AK; Pal, D, 2007
)
0.34
" In continuation of the tests investigating the factors limiting bioavailability of boswellic acids, the present study examined the permeability of KBA and AKBA in human Caco-2 cell lines."( Permeation of Boswellia extract in the Caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1B3 and MRP2.
Abdel-Tawab, M; Fricker, G; Hummel, J; Kanzer, J; Krüger, P; Schubert-Zsilavecz, M, 2009
)
0.35
" These findings may be valuable in developing formulation strategies to optimize ocular bioavailability of topically administered ocular agents."( Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux.
Herndon, BL; Karla, PK; Mitra, A; Pal, D; Quinn, TL; Thomas, P, 2009
)
0.35
" In this investigation, to explore new methods for route-to-route extrapolation, the bioavailability of MK-0679, a leukotriene D(4) receptor antagonist, was compared following iv, po, intranasal (in), or intratracheal (it) administration."( Investigations of the use of bioavailability data to adjust occupational exposure limits for active pharmaceutical ingredients.
Dixit, R; Hu, SC; Naumann, BD; Sarangapani, R; Sargent, EV; Weideman, PA, 2009
)
0.35
" Such clarification may lead to the development of strategies to overcome efflux and enhance its bioavailability at target site."( Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.
Kwatra, D; Mitra, AK; Pal, D; Vadlapatla, RK; Vadlapudi, AD, 2010
)
0.36
" PDE-310 exhibited high oral bioavailability (>70%) and was distributed well to various tissues except brain and testis."( Preclinical pharmacokinetics of PDE-310, a novel PDE4 inhibitor.
Ahn, SH; Bae, MA; Cheon, HG; Jeon, DJ; Kim, MS; Kwon, KI; Lee, BH; Park, JS; Rho, HJ; Seo, JW; Song, JS, 2011
)
0.37
"Emodin is a poorly bioavailable but promising plant-derived anticancer drug candidate."( Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin.
Feng, Q; Hu, M; Li, Y; Liu, W; Liu, Z; Ye, L, 2012
)
0.38
"Ginsenoside compound K (CK) is a bioactive compound with poor oral bioavailability due to its high polarity, while its novel ester prodrugs, the butyl and octyl ester (CK-B and CK-O), are more lipophilic than the original drug and have an excellent bioavailability."( Absorption mechanism of ginsenoside compound K and its butyl and octyl ester prodrugs in Caco-2 cells.
Deng, ZY; Hu, JN; Li, HY; Li, W; Liu, XR; Luo, T; Ye, H; Zhang, B; Zheng, YN; Zhu, XM, 2012
)
0.38
"It may be concluded that BCRP plays an important role in the intestinal efflux of MED-5 and limits the bioavailability after oral administration of MED-15."( Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability.
Li, X; Liu, D; Rong, Z; Xiang, D; Xu, Y; Zhang, C, 2013
)
0.39
" In summary, our results clearly demonstrate, for the first time, that poor bioavailability of these three prenylated flavonoids is the result of poor intrinsic permeability and efflux by apical efflux transporters."( Study on the mechanism of intestinal absorption of epimedins a, B and C in the Caco-2 cell model.
Chen, Y; Gao, X; Liu, C; Qu, D; Wang, Y; Zhou, J, 2014
)
0.4
"Bazedoxifene, a novel selective estrogen receptor modulator, has complex pharmacokinetics with rapid absorption, high metabolic clearance, low oral bioavailability (6."( Efflux and uptake transporters involved in the disposition of bazedoxifene.
Berginc, K; Kristl, A; Lušin, TT; Mrhar, A; Stieger, B; Trontelj, J, 2016
)
0.43
"Concurrent oral administration of (+)-catechin and puerarin significantly increased the absolute oral bioavailability of puerarin, but decreasing that of (+)-catechin."( Absorptive interactions of concurrent oral administration of (+)-catechin and puerarin in rats and the underlying mechanisms.
Fu, Y; Gong, T; Lin, Q; Su, HF; Sun, X; Wang, XY; Zhang, ZR, 2016
)
0.43

Dosage Studied

The metabolites described above were all detected in bile collected from a rat dosed with verlukast. Approximately 80% of the dose was recovered up to 4 hr postdose.

ExcerptRelevanceReference
" The metabolites described above were all detected in bile collected from a rat dosed with verlukast."( In vitro and in vivo biotransformations of the potent leukotriene D4 antagonist verlukast in the rat.
Nicoll-Griffith, D; Rasori, R; Trimble, L; Williams, H; Yergey, J; Zamboni, R,
)
0.58
" dosage regimen."( Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man.
Buntinx, A; De Lepeleire, I; De Schepper, PJ; Depré, M; Hsieh, JY; Margolskee, DJ; Rogers, JD; Van Hecken, A, 1992
)
0.28
" Thirty minutes later a beta 2-agonist dose-response curve was performed by inhaling salbutamol in cumulative doses of 200, 400 and 800 micrograms."( Bronchodilator properties of an inhaled leukotriene D4 antagonist (verlukast--MK-0679) in asthmatic patients.
Buntinx, A; De Lepeleire, I; Decramer, M; Friedman, B; Lammers, JW; Van Daele, P; Van den Elshout, FM, 1992
)
0.52
" In asthmatic subjects, 28 mg MK-571 caused a significant, at least 44-fold, rightward shift of the dose-response curve to LTD4, whereas 277 mg shifted the dose-response curve at least 84-fold to the right."( MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human.
Buntinx, A; De Lepeleire, I; Joos, GF; Kips, JC; Margolskee, DJ; Pauwels, RA; Van der Straeten, ME, 1991
)
0.28
" Dose-response curves for LTD4 (12-240 ng/min) on coronary flow were shifted to the left in rats with permanent coronary occlusion for 8 wk or with coronary occlusion for 30 or 60 min and reperfusion for 4 wk."( Effects of LTD4 and its specific antagonist L-660,711 in isolated rat hearts with chronic myocardial infarction.
Ertl, G; Gaudron, P; Han, H; Hu, K; Neubauer, S; Tian, R, 1994
)
0.29
" In bile collected from rats dosed intravenously with 50 mg/kg of verlukast, approximately 80% of the dose was recovered up to 4 hr postdose."( Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile.
Gupta, N; Nicoll-Griffith, DA; Trimble, LA; Twa, SP; Williams, H; Yergey, JA, 1995
)
1.97
" Priming of hMCs with IL-4 for 5 days enhances their sensitivity to each agonist, but preferentially lowers their threshold for activation by LTC(4) and UDP (approximately 3 log(10)-fold shifts in dose-response for each agonist) over LTD(4) (1."( Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells.
Austen, KF; Boyce, JA; Maekawa, A; Mellor, EA, 2001
)
0.31
"In different groups of portally perfused control and cirrhotic rat livers, the following were analyzed: a portal perfusion pressure (PP) dose-response curve to LTD4; the effects on PP caused by either vehicle, the selective 5-lipoxygenase inhibitor AA-861, the selective Cys-LT1 receptor antagonist MK-571, or the dual Cys-LT1 and Cys-LT2 receptor antagonist BAY u9773; and immunohistochemistry for 5-lipoxygenase in liver sections of cirrhotic and control livers."( 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes.
Bosch, J; Claria, J; García-Pagán, JC; Graupera, M; Massaguer, A; Rodés, J; Titos, E, 2002
)
0.31
" From dose-response curves with Sf9 membrane vesicles, glutathionylcurcumin conjugates appeared to be less potent inhibitors of MRP1 and MRP2 than their parent compound curcumin."( Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin.
Boersma, MG; Cnubben, NH; Rietjens, IM; Spenkelink, B; Usta, M; van Bladeren, PJ; van der Velde, AE; van Zanden, JJ; Wortelboer, HM, 2003
)
0.32
" Dose-response curves for transport and the ratio of dye concentration in the secreted fluid to that in the bathing medium (S/M) were determined for Texas Red as well as for P-gp substrates (rhodamine 123, daunorubicin), the organic anion fluorescein and the organic cation quinacrine."( Transepithelial transport of fluorescent p-glycoprotein and MRP2 substrates by insect Malpighian tubules: confocal microscopic analysis of secreted fluid droplets.
Leader, JP; O'Donnell, MJ, 2005
)
0.33
"4% in rats, with non-linear pharmacokinetics when its dosage increased."( Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Chen, X; Chowbay, B; Duan, W; Li, CG; Liang, J; Lin, SG; Liu, PQ; Wen, JY; Yu, XY; Zhou, SF; Zhou, ZW, 2007
)
0.34
" The effects of P-glycoprotein (P-gp), multidrug resistance-associated protein 2 (MRP2), and breast cancer resistance protein (BCRP) inhibitors on sulfasalazine bidirectional permeability were studied across Caco-2 cell monolayers, including dose-response analysis."( Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Amidon, GL; Dahan, A, 2009
)
0.35
" Depo-Provera-synchronized mice were dosed vaginally or intraperitoneally with (3)H-TFV, with or without MK571 co-administration, to delineate the function of cervicovaginal Mrp4."( Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing.
Hu, M; Pearlman, A; Rohan, LC; Zhou, T, 2016
)
0.43
" CDFDA dosing models were based on simultaneous fitting of CDF levels in apical, basolateral, and intracellular compartments."( Cellular Pharmacokinetic Model-Based Analysis of Genistein, Glyceollin, and MK-571 Effects on 5 (and 6)-Carboxy-2',7'-Dichloroflourescein Disposition in Caco-2 Cells.
Drennen, C; Gorse, E; Stratford, RE, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Multidrug resistance-associated protein 1 Homo sapiens (human)IC50 (µMol)2.80000.00153.71109.6600AID643322
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (23)

Processvia Protein(s)Taxonomy
leukotriene metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
response to xenobiotic stimulusMultidrug resistance-associated protein 1 Homo sapiens (human)
cobalamin transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid biosynthetic processMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to oxidative stressMultidrug resistance-associated protein 1 Homo sapiens (human)
heme catabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transportMultidrug resistance-associated protein 1 Homo sapiens (human)
phospholipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
positive regulation of inflammatory responseMultidrug resistance-associated protein 1 Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cell chemotaxisMultidrug resistance-associated protein 1 Homo sapiens (human)
transepithelial transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cyclic nucleotide transportMultidrug resistance-associated protein 1 Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 1 Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to amyloid-betaMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
ATP bindingMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type vitamin B12 transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basal plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
lateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
extracellular exosomeMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1318758Induction of peroxisomal enzyme activity in mouse assessed as increase in fatty acyl Co-A oxidase activity at 400 mg/kg, po for 4 days2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.
AID1698007Ratio of drug level in human blood to plasma administered through iv dosing by LC-MS/MS analysis
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1698001Lipophilicity, log D of the compound at pH 7.4 by by shake flask method
AID643322Inhibition of MRP1 expressed in MDCK cells assessed as calcein AM accumulation after 30 mins by fluorescence assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Potent galloyl-based selective modulators targeting multidrug resistance associated protein 1 and P-glycoprotein.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1698010Hepatic clearance in human administered through iv dosing
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1698006Ratio of drug level in cynomolgus monkey blood to plasma administered through iv dosing by LC-MS/MS analysis
AID1698011Fraction unbound in human plasma
AID1698000Apparent permeability in dog MDCKII-LE cells at pH 7.4
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID54896Binding affinity against Cysteinyl leukotriene D4 receptor from guinea pig lung membrane1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Stereospecific synthesis, assignment of absolute configuration, and biological activity of the enantiomers of 3-[[[3-[2-(7-chloroquinolin-2-yl)-(E)-ethenyl]phenyl] [[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid, a potent and specific leuk
AID1698009Hepatic clearance in cynomolgus monkey at < 1 mg/kg, iv administered as cassette dosing
AID1318757Displacement of [3H]LTD4 from LTD4 receptor in guinea pig lung membrane2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.
AID55231In vitro inhibitory activity against Cysteinyl leukotriene D4 receptor from human lung membrane1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Stereospecific synthesis, assignment of absolute configuration, and biological activity of the enantiomers of 3-[[[3-[2-(7-chloroquinolin-2-yl)-(E)-ethenyl]phenyl] [[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid, a potent and specific leuk
AID176823Tested for antigen-induced dyspnea in hyperactive rats1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Stereospecific synthesis, assignment of absolute configuration, and biological activity of the enantiomers of 3-[[[3-[2-(7-chloroquinolin-2-yl)-(E)-ethenyl]phenyl] [[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid, a potent and specific leuk
AID1698004Fraction unbound in cynomolgus monkey plasma
AID80461Antagonist activity of LTD4-induced contractions of isolated guinea pig trachea1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Stereospecific synthesis, assignment of absolute configuration, and biological activity of the enantiomers of 3-[[[3-[2-(7-chloroquinolin-2-yl)-(E)-ethenyl]phenyl] [[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid, a potent and specific leuk
AID1698002Intrinsic clearance in cryopreserved human hepatocytes at 1 uM measured up to 120 mins by LC-MS/MS analysis
AID1697999Dissociation constant, acidic pKa of compound measured up to 18 mins by capillary electrophoresis
AID1698016Dissociation constant, basic pKa of compound measured up to 18 mins by capillary electrophoresis
AID1346031Human CysLT1 receptor (Leukotriene receptors)1999Nature, Jun-24, Volume: 399, Issue:6738
Characterization of the human cysteinyl leukotriene CysLT1 receptor.
AID1345163Human OATP2B1 (SLCO family of organic anion transporting polypeptides)2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (379)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (1.06)18.7374
1990's98 (25.86)18.2507
2000's154 (40.63)29.6817
2010's112 (29.55)24.3611
2020's11 (2.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.83 (24.57)
Research Supply Index6.02 (2.92)
Research Growth Index6.22 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (3.54%)5.53%
Reviews9 (2.27%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other373 (94.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]